Chinese Role in U.S. Cannabis Industry Investigation — Policy & National Security

Executive Summary

Republican senators have formally requested a federal investigation into Chinese involvement in the U.S. cannabis and hemp industries, citing national security concerns and potential violations of federal drug laws. The October 2026 request, led by senior GOP members of key Senate committees, calls on the Department of Justice, Drug Enforcement Administration, and Department of Homeland Security to examine Chinese investment patterns, supply chain dependencies, and potential illicit activities within America's rapidly expanding legal cannabis sector. The investigation demand comes as the U.S. cannabis industry approaches $30 billion in annual sales, with hemp-derived products adding billions more. Senators specifically highlighted concerns about Chinese ownership stakes in cultivation facilities, manufacturing operations, and retail chains across multiple states, as well as the sourcing of equipment, genetics, and chemical precursors from Chinese suppliers. This marks the first comprehensive congressional call for scrutiny of foreign involvement in state-legal cannabis operations, raising questions about how federal agencies will navigate the conflict between state legalization frameworks and federal prohibition while addressing national security priorities.

Why This Investigation Matters

The investigation request affects thousands of cannabis operators, millions of patients and consumers, and billions in capital flows while testing the boundaries of federal enforcement in state-legal markets. The U.S. cannabis industry now operates in 38 states with medical programs and 24 states with adult-use legalization, employing over 428,000 workers according to industry data. Any federal investigation into ownership structures and supply chains could trigger compliance audits, license revocations, and criminal referrals that destabilize businesses operating under state law. Multi-state operators with Chinese investment exposure face potential divestiture requirements or federal scrutiny that could freeze expansion plans and crater valuations. For patients, disruption to supply chains could affect access to medical cannabis products, particularly specialized formulations and consistent genetics that rely on international sourcing. The hemp industry, which Congress explicitly legalized through the 2018 Farm Bill, faces particular uncertainty as CBD manufacturers depend heavily on Chinese suppliers for extraction equipment, packaging materials, and chemical testing reagents. The investigation also represents a significant escalation in the intersection of cannabis policy and national security concerns. Previous federal enforcement focused primarily on violations of the Controlled Substances Act, 21 U.S.C. § 812, and money laundering statutes. This request introduces foreign investment screening, intellectual property theft, and potential espionage concerns into cannabis enforcement calculus, potentially triggering Committee on Foreign Investment in the United States review processes that have historically exempted cannabis due to its Schedule I status. Capital markets are watching closely as institutional investors assess whether Chinese supply chain exposure creates new compliance risks. Cannabis companies traded on Canadian exchanges and U.S. over-the-counter markets saw immediate volatility following the investigation announcement, with particular pressure on vertically integrated operators known to source cultivation equipment and genetics internationally.

Background and History: Foreign Investment in U.S. Cannabis

Chinese involvement in U.S. cannabis operations evolved gradually over the past decade as state legalization created a multi-billion dollar industry operating in legal gray zones that traditional U.S. financial institutions largely avoided.

Early State Legalization and Capital Gaps (2012-2016)

When Colorado and Washington became the first states to legalize adult-use cannabis in 2012, federal prohibition under the Controlled Substances Act created a capital vacuum. Traditional banks refused accounts due to potential money laundering charges under 18 U.S.C. § 1956, and institutional investors avoided the sector entirely. This financing gap opened opportunities for alternative capital sources, including foreign investors willing to navigate legal ambiguity for high returns. The Obama administration's 2013 Cole Memorandum provided limited enforcement guidance, deprioritizing federal prosecution of state-compliant operators. This created a window for international investment, though most remained indirect through Canadian intermediaries or complex corporate structures designed to insulate foreign investors from direct U.S. legal exposure.

Hemp Legalization and Chinese Supply Chains (2018)

The Agriculture Improvement Act of 2018, commonly known as the 2018 Farm Bill, removed hemp and hemp-derived products from Schedule I, explicitly legalizing cultivation and commerce in cannabis plants containing less than 0.3% delta-9 THC. This created immediate demand for industrial-scale processing equipment, extraction technology, and testing infrastructure. Chinese manufacturers quickly dominated the hemp equipment market, offering cultivation systems, CO2 extraction machines, and chromatography equipment at price points 40-60% below U.S. and European competitors. By 2020, industry estimates suggested 70% of hemp processing equipment in U.S. facilities originated from Chinese manufacturers, creating supply chain dependencies that persisted even as geopolitical tensions escalated.

COVID-19 and Supply Chain Vulnerabilities (2020-2021)

The pandemic exposed deep dependencies on Chinese manufacturing across multiple sectors, including cannabis. Cultivation facilities faced months-long delays for LED grow lights, HVAC systems, and automated trimming equipment. Testing laboratories struggled to source reagents and consumables for potency and contaminant analysis. The disruptions highlighted how thoroughly Chinese suppliers had penetrated cannabis supply chains, even as federal prohibition prevented most U.S. cannabis companies from accessing Small Business Administration pandemic relief programs.

SAFE Banking Failures and Alternative Capital (2021-2024)

Repeated failures of the Secure and Fair Enforcement Banking Act in Congress perpetuated cannabis industry exclusion from traditional banking. Each legislative defeat pushed operators toward alternative financing, including private equity structures that sometimes obscured ultimate beneficial ownership. State regulators, focused primarily on preventing criminal infiltration and diversion to illegal markets, generally lacked resources and authority to conduct deep due diligence on foreign investment sources.

MSO Expansion and Equipment Standardization (2022-2025)

As multi-state operators expanded to 10, 15, or 20+ state markets, operational standardization became critical for efficiency and quality control. Many MSOs adopted Chinese-manufactured cultivation systems across their entire footprint, creating economies of scale but also single-source dependencies. Genetic libraries, often developed in partnership with international breeders, sometimes involved Chinese research institutions with expertise in plant genetics and tissue culture.

Congressional Attention Emerges (2025-2026)

Broader congressional focus on Chinese economic influence, particularly regarding fentanyl precursor chemicals and synthetic drug manufacturing, gradually expanded to include cannabis. The same Senate committees investigating Chinese involvement in opioid supply chains began examining whether similar patterns existed in legal and illegal cannabis markets. Staff investigations revealed ownership stakes in cultivation facilities, retail chains, and ancillary businesses that had not triggered foreign investment reviews due to cannabis's federally illegal status excluding it from normal CFIUS processes.

Key Players in the Investigation Demand

Senate Republican Leadership

The investigation request originated from Republican members of the Senate Judiciary Committee and Senate Homeland Security and Governmental Affairs Committee, according to reporting on the October 2026 announcement. While specific senator names were not detailed in initial reports, the request carries weight due to the committees' oversight jurisdiction over the Department of Justice, DEA, and DHS. These committees have subpoena power and can compel testimony from agency officials and private sector witnesses.

Department of Justice

The DOJ faces the complex task of investigating activities that violate federal law (cannabis commerce) while potentially involving additional violations (foreign investment disclosure failures, money laundering, sanctions evasion). The department's Criminal Division and National Security Division would likely coordinate any investigation, creating unusual overlap between drug enforcement and counterintelligence priorities. The DOJ has historically relied on U.S. Attorneys' offices to exercise prosecutorial discretion in cannabis cases, but a national security investigation could centralize decision-making in Washington.

Drug Enforcement Administration

The DEA maintains regulatory authority over all Schedule I controlled substances, including cannabis. The agency's Diversion Control Division licenses legitimate handlers of controlled substances, but state-legal cannabis operators cannot obtain federal licenses due to marijuana's Schedule I status. An investigation into Chinese involvement would require DEA coordination with state regulators who actually license and oversee cannabis businesses, creating potential friction over information sharing and enforcement priorities.

Department of Homeland Security

DHS involvement signals concern about border security, customs enforcement, and potential sanctions violations. U.S. Customs and Border Protection, a DHS component, already seizes cannabis products at ports of entry and international mail facilities. An expanded investigation might examine whether Chinese entities are exploiting hemp legalization to import higher-THC products mislabeled as compliant hemp, or whether equipment imports contain surveillance technology or intellectual property theft mechanisms.

State Regulatory Agencies

State cannabis control boards in California, Colorado, Michigan, Oklahoma, and other major markets maintain detailed ownership records, supply chain tracking data, and financial disclosures from licensed operators. Federal investigators would need state cooperation to access these records, but states have sometimes resisted federal information requests that could expose state-legal operators to federal prosecution. The tension between state sovereignty over cannabis regulation and federal national security concerns creates jurisdictional complexity.

Multi-State Operators

Publicly traded MSOs including Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings operate hundreds of dispensaries and cultivation facilities across multiple states. These companies maintain detailed supply chain records and ownership disclosures required by state regulators and securities laws. Any investigation would likely examine their vendor relationships, equipment sourcing, and investor composition. Private MSOs and single-state operators with less public disclosure may face more intensive scrutiny.

Hemp and CBD Companies

The hemp industry, legal under federal law since 2018, includes thousands of farmers, processors, and product manufacturers. Companies like Charlotte's Web, cbdMD, and Lazarus Naturals source equipment, packaging, and ingredients internationally. Hemp businesses have generally operated with less regulatory scrutiny than state-licensed cannabis operators, potentially creating gaps in ownership transparency and supply chain documentation.

Chinese Equipment Manufacturers

Companies including Shenzhen Herifi Technology, Kingbo Strike Technology, and numerous other Chinese manufacturers supply LED grow lights, extraction equipment, and cultivation systems to U.S. cannabis operators. These companies operate legally under Chinese law and U.S. import regulations, but investigation focus may examine whether equipment contains surveillance capabilities, whether sales violate U.S. sanctions, or whether technology transfer agreements involve intellectual property concerns.

Legal and Regulatory Framework

The investigation operates within a complex legal landscape where state-legal cannabis commerce violates federal law, creating jurisdictional tensions and enforcement discretion questions that complicate traditional national security oversight mechanisms. The Controlled Substances Act, 21 U.S.C. § 801 et seq., classifies marijuana as a Schedule I controlled substance, defining it as having no accepted medical use and high abuse potential. This classification makes all cultivation, distribution, and possession federal crimes, regardless of state law. Penalties under 21 U.S.C. § 841 include up to life imprisonment for large-scale cultivation or distribution, though federal prosecutors have generally exercised discretion to avoid prosecuting state-compliant operators. The Rohrabacher-Farr Amendment, renewed annually in appropriations bills since 2014, prohibits the Department of Justice from using federal funds to prevent states from implementing their own medical cannabis laws. This spending restriction limits but does not eliminate federal enforcement authority, and does not apply to adult-use programs or to investigations focused on national security rather than drug enforcement. The Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA) expanded the Committee on Foreign Investment in the United States' authority to review foreign investments in U.S. businesses, particularly those involving critical infrastructure, sensitive personal data, or proximity to sensitive government facilities. However, CFIUS has generally not reviewed cannabis investments because federally illegal businesses cannot be considered legitimate U.S. businesses under the statutory framework. This creates a gap where foreign investment in cannabis avoids the scrutiny applied to other sectors. The Bank Secrecy Act, 31 U.S.C. § 5311 et seq., requires financial institutions to report suspicious activities and maintain records of transactions. Financial Crimes Enforcement Network guidance from 2014 established that banks serving cannabis businesses must file Suspicious Activity Reports and conduct enhanced due diligence. These SARs create a paper trail of cannabis financial activities, but most banks still refuse cannabis accounts due to potential money laundering liability under 18 U.S.C. § 1956 and 1957. The International Emergency Economic Powers Act, 50 U.S.C. § 1701 et seq., authorizes the president to regulate commerce with foreign nations during national emergencies. Various executive orders have imposed sanctions on Chinese individuals and entities related to fentanyl trafficking, human rights abuses, and military-civil fusion activities. Investigation focus may examine whether any Chinese investment in U.S. cannabis involves sanctioned entities or individuals. The Agricultural Improvement Act of 2018, 7 U.S.C. § 1639o et seq., removed hemp from the Controlled Substances Act and established a federal regulatory framework under the U.S. Department of Agriculture. This created a legal distinction between hemp (cannabis with ≤0.3% delta-9 THC) and marijuana (cannabis exceeding that threshold), but enforcement challenges persist around hemp-derived intoxicating cannabinoids like delta-8 THC and THCA. State cannabis laws vary dramatically in their ownership disclosure requirements, residency restrictions, and background check processes. California requires detailed ownership disclosure for any person or entity with 20% or more ownership interest. Oklahoma initially allowed out-of-state and foreign ownership with minimal restrictions, though later reforms tightened requirements. Michigan requires disclosure of all individuals with direct or indirect ownership or control. These varying standards create inconsistent transparency across the national cannabis industry.

State-by-State Foreign Investment Landscape

State cannabis programs vary dramatically in their foreign ownership restrictions, residency requirements, and disclosure mandates, creating a patchwork regulatory environment that complicates federal investigation efforts.

California

California's cannabis regulations under the Department of Cannabis Control require disclosure of all individuals and entities with 20% or more ownership interest in licensed businesses. The state does not explicitly prohibit foreign ownership, but federal law complications make foreign investment rare in direct license-holding entities. California's massive market, exceeding $5 billion in annual legal sales, makes it a priority focus for any investigation. The state's extensive supply chain includes significant equipment sourcing from international manufacturers.

Oklahoma

Oklahoma initially implemented one of the most permissive medical cannabis programs in the nation, with minimal residency requirements and relatively open ownership rules. This attracted significant out-of-state and potentially foreign investment, leading to rapid proliferation of cultivation facilities and dispensaries. The Oklahoma Medical Marijuana Authority has since implemented stricter ownership disclosure and residency requirements following concerns about illegal diversion and foreign control. The state's experience illustrates regulatory evolution in response to ownership transparency concerns.

Michigan

Michigan requires all cannabis license applicants to disclose individuals with direct or indirect control, including beneficial owners, officers, directors, and managers. The state's Cannabis Regulatory Agency conducts background checks and financial reviews, but foreign ownership is not explicitly prohibited. Michigan's adult-use market has grown rapidly since 2019, with significant capital investment in cultivation and processing infrastructure that may include international equipment sourcing.

Colorado

Colorado, as the first state to implement adult-use legalization in 2014, maintains mature regulatory oversight through the Marijuana Enforcement Division. The state requires extensive ownership disclosure and background checks, with particular scrutiny of out-of-state investors. Colorado's long regulatory history provides detailed records that could assist federal investigators examining ownership evolution and supply chain patterns over the past decade.

Massachusetts

Massachusetts requires detailed disclosure of all individuals and entities with direct or indirect control over cannabis licensees, including passive investors above certain ownership thresholds. The Cannabis Control Commission conducts extensive background reviews and financial audits. The state's relatively high barriers to entry have limited the number of licenses issued, potentially reducing but not eliminating foreign investment exposure.

Illinois

Illinois implemented adult-use legalization in 2020 with a social equity focus and competitive licensing process. The state requires detailed ownership disclosure and background checks, with particular attention to financial sources. Illinois's relatively recent market entry means newer infrastructure and equipment purchases that may reflect current supply chain patterns.

New York

New York's adult-use market launched in 2022 with extensive social equity provisions and strict licensing requirements. The Office of Cannabis Management requires detailed ownership disclosure and conducts thorough background investigations. New York's market is still developing, with ongoing licensing rounds that could be affected by enhanced federal scrutiny of foreign investment.

Florida

Florida operates a medical-only program with a limited number of vertically integrated licenses held by large operators. The state requires extensive background checks and ownership disclosure through the Department of Health's Office of Medical Marijuana Use. Florida's large patient population and limited license structure have created high-value operations that may attract sophisticated investment structures.

Market and Business Implications

The investigation demand creates immediate uncertainty for cannabis operators, equipment suppliers, and investors while potentially reshaping capital flows and supply chain strategies across the $30 billion U.S. cannabis industry. Multi-state operators face the most immediate pressure to audit their supply chains and investor bases. Companies with Chinese-manufactured equipment in their cultivation facilities must assess whether enhanced scrutiny could trigger compliance reviews or create public relations challenges. Those with indirect Chinese investment through private equity structures or offshore vehicles face potential pressure to restructure ownership or provide enhanced disclosure to state regulators and federal investigators. Equipment suppliers and ancillary service providers must evaluate their sourcing strategies. The cannabis industry's historical exclusion from traditional banking and capital markets pushed many operators toward cost-conscious purchasing decisions, making Chinese manufacturers' 40-60% price advantages attractive. Any investigation findings that create compliance concerns around Chinese equipment could force operators to source from more expensive domestic or European suppliers, increasing capital costs and potentially affecting product pricing. The hemp and CBD industry faces particular uncertainty because federal legality under the 2018 Farm Bill has enabled more open international commerce than state-legal cannabis programs allow. Hemp processors who have built operations around Chinese extraction equipment and testing instruments may face difficult decisions about equipment replacement if investigation findings suggest national security or compliance risks. Capital markets are already responding with increased due diligence around foreign investment exposure. Cannabis companies seeking to raise capital through private placements or public offerings may face investor questions about supply chain dependencies and ownership transparency. Some institutional investors who have recently entered cannabis through debt financing or minority equity stakes may pause additional deployments pending investigation clarity. Vertically integrated operators with in-house cultivation, processing, and retail operations face different risk profiles than single-function businesses. Those who control their entire supply chain and source equipment domestically have less exposure to investigation findings, potentially creating competitive advantages. Conversely, operators who have achieved efficiency through international sourcing and standardized Chinese equipment across multiple facilities face concentrated risk. The investigation also affects cannabis real estate investment trusts and landlords who lease property to cultivation and processing facilities. Any federal enforcement actions that result in license revocations or business closures could trigger lease defaults and property value declines. Real estate investors are scrutinizing tenant supply chains and ownership structures with new intensity. Insurance carriers serving the cannabis industry may adjust underwriting criteria and pricing based on investigation developments. Policies covering business interruption, product liability, and directors and officers liability could see premium increases or coverage restrictions for operators with significant foreign supply chain exposure or ownership complexity. State tax revenues from cannabis sales, which exceeded $3.7 billion nationally in 2025, could face pressure if investigation findings disrupt operations or slow market growth. States that have built budget assumptions around continued cannabis revenue growth may need to reassess projections if federal scrutiny creates market uncertainty.

What Experts and Stakeholders Say

Industry representatives, national security analysts, and policy experts offer divergent perspectives on the investigation's necessity, scope, and potential consequences for cannabis markets and regulatory frameworks. Cannabis industry trade associations have emphasized that state-licensed operators undergo extensive background checks and regulatory oversight, arguing that additional federal investigation is unnecessary and potentially harmful to legitimate businesses serving patients and consumers. According to industry representatives, the investigation request conflates distinct issues: legitimate equipment sourcing from international manufacturers, which occurs across all U.S. industries; potential foreign investment in licensed operations, which state regulators already scrutinize; and illegal market activities, which merit enforcement but should not taint legal operators. National security analysts have noted that Chinese involvement in U.S. cannabis markets follows patterns seen in other sectors, including agriculture, pharmaceuticals, and technology. According to this perspective, cannabis industry exclusion from traditional banking and capital markets created vulnerabilities that foreign actors could exploit, whether for economic gain, intelligence collection, or influence operations. The lack of CFIUS review for cannabis investments represents a genuine gap in foreign investment screening that merits attention regardless of cannabis's legal status. State regulators have expressed concern that federal investigation could undermine state sovereignty over cannabis policy and create chilling effects on legitimate business operations. According to state officials, cannabis control boards maintain detailed ownership records, conduct background investigations, and track products from seed to sale through sophisticated systems. Federal demands for state-held data could expose state-compliant operators to federal prosecution, creating tensions between state regulatory cooperation and protection of state-legal industries. Banking compliance experts have observed that cannabis industry exclusion from traditional financial services created the conditions for ownership opacity and alternative capital sources that now generate concern. According to this analysis, passage of the SAFE Banking Act or similar legislation would bring cannabis financial activities into regulated banking channels with standard anti-money laundering controls and beneficial ownership disclosure, addressing many concerns more effectively than investigation and enforcement. Civil liberties advocates have warned that investigation into Chinese involvement in cannabis could serve as pretext for broader federal enforcement against state-legal cannabis programs, particularly if a future administration opposes legalization. According to this perspective, national security framing could be used to circumvent appropriations restrictions on DOJ interference with state medical cannabis programs and to justify enforcement actions that would be politically controversial if pursued solely on drug policy grounds. Supply chain analysts have noted that Chinese manufacturing dominance in cannabis equipment reflects broader U.S. industrial capacity challenges rather than cannabis-specific issues. According to industry observers, domestic manufacturers largely avoided cannabis markets due to federal prohibition and banking complications, ceding market share to Chinese companies willing to navigate legal ambiguity. Rebuilding domestic supply chains would require significant capital investment and time, creating transition challenges if investigation findings prompt rapid sourcing changes.

What Comes Next: Investigation Timeline and Scenarios

The investigation request initiates a process that could unfold over months or years, with outcomes ranging from narrow enforcement actions to comprehensive regulatory reforms affecting the entire cannabis industry. The immediate next step involves agency responses to the congressional request. The Department of Justice, DEA, and DHS must decide whether to launch formal investigations, assign existing resources to examine the issues, or respond that current enforcement priorities and legal constraints limit their ability to investigate state-legal cannabis operations. Agency responses typically occur within 30-90 days of congressional requests, though timelines vary based on political dynamics and resource availability. If agencies proceed with investigations, initial phases would likely involve information gathering from state regulators, review of existing financial intelligence from FinCEN's cannabis-related SAR database, and examination of import records for cannabis equipment and supplies. Investigators might issue subpoenas to cannabis companies for ownership documents, vendor contracts, and financial records. This phase could take six months to a year, depending on scope and cooperation levels. Congressional oversight hearings could occur in parallel with agency investigations, bringing cannabis industry representatives, state regulators, and national security experts to testify about foreign investment patterns and supply chain dependencies. These hearings would generate public attention and political pressure that could influence both agency investigation priorities and broader cannabis policy debates. Several scenarios could emerge from the investigation process: **Narrow enforcement actions** might target specific bad actors found to involve sanctioned Chinese entities, money laundering, or other clear violations beyond cannabis's Schedule I status. This outcome would create compliance lessons for the industry but avoid broad disruption to state-legal markets. **Supply chain recommendations** might result in agency guidance encouraging or requiring cannabis operators to source equipment domestically or from allied nations, similar to restrictions in other sensitive sectors. This would increase costs but could be implemented gradually without immediate enforcement actions. **Ownership disclosure reforms** might prompt state regulators to enhance beneficial ownership transparency requirements, potentially with federal technical assistance or model regulations. This would address concerns about foreign investment without direct federal enforcement against state-legal operators. **CFIUS expansion** could involve legislative or regulatory changes to bring cannabis businesses under foreign investment review, despite federal prohibition. This would require resolving the legal contradiction of applying national security oversight to federally illegal activities. **Broader enforcement revival** represents the most disruptive scenario, where investigation findings become justification for renewed federal prosecution of state-legal cannabis operations, particularly those with foreign investment or supply chain connections. This would mark a dramatic reversal of the enforcement discretion that has prevailed since the Cole Memorandum era. **Legislative responses** might emerge from either party. Republicans might pursue restrictions on foreign involvement in cannabis as part of broader China competition legislation. Democrats might argue that investigation findings demonstrate the need for cannabis banking reform and federal legalization to bring the industry into regulated channels with standard oversight. The 2026 election cycle and potential administration changes in 2027 will significantly affect investigation trajectory and outcomes. A new administration could deprioritize the investigation, expand it, or use findings to support preferred policy directions on cannabis legalization or prohibition.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• Agriculture Improvement Act of 2018 (Farm Bill), Public Law 115-334 — https://www.congress.gov/bill/115th-congress/house-bill/2
• Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA) — https://home.treasury.gov/policy-issues/international/the-committee-on-foreign-investment-in-the-united-states-cfius/firrma
• FinCEN Guidance: BSA Expectations Regarding Marijuana-Related Businesses (2014) — https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• Cole Memorandum on Marijuana Enforcement (2013, rescinded 2018) — https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
• U.S. Department of Agriculture Hemp Production Program — https://www.ams.usda.gov/rules-regulations/hemp
• Congressional Research Service: Marijuana and the Controlled Substances Act — https://crsreports.congress.gov
• National Conference of State Legislatures: State Medical Cannabis Laws — https://www.ncsl.org/health/state-medical-cannabis-laws
• Senate Judiciary Committee — https://www.judiciary.senate.gov
• Senate Homeland Security and Governmental Affairs Committee — https://www.hsgac.senate.gov
• Drug Enforcement Administration Diversion Control Division — https://www.deadiversion.usdoj.gov
• Committee on Foreign Investment in the United States — https://home.treasury.gov/policy-issues/international/the-committee-on-foreign-investment-in-the-united-states-cfius